Since our last edition, our portfolio companies have reached important technical, commercial, and operational milestones. From technological validation and product launches to industrial scale-up and growing market traction, these developments reflect both the depth of execution and the momentum building across the portfolio.
NxLite Opens Advanced Innovation & Manufacturing Center
NxLite has opened its new Advanced Innovation & Manufacturing (AIM) Center in Canton, Michigan. The 4,200 m² facility will serve as the company’s U.S. headquarters, housing nano-coating production lines and a materials science R&D center. The $9 million investment will enable NxLite to scale production of its permanent, energy-saving low-emissivity (low-E) nano-coatings for glass and polymers. These coatings are applicable in buildings, transportation, and refrigeration, and can be used on both glass and lightweight polymer substrates such as PMMA and polycarbonate.
NxLite was recently named to the 2024 Cleantech 50 to Watch by the Cleantech Group and selected as the Top Building & Infrastructure Technologies Venture at the C3 Summit. With its AIM Center now operational and global partnerships in place, the company is positioned to accelerate the deployment of its energy-efficient technology across multiple industries.
Picus Security Launches Picus Exposure Validation
Picus Security has launched Picus Exposure Validation, a new capability that allows security teams to verify the exploitability of vulnerabilities based on their unique environments. It continuously tests security controls against real-world attack techniques and identifies which vulnerabilities are truly exploitable and which can safely be deprioritized. More than 40,000 new Common Vulnerabilities and Exposures (CVEs) were disclosed in 2024, and 61 percent of them were labelled high or critical. Traditional approaches rely on indicators like CVSS and EPSS, but Picus Exposure Validation replaces assumptions with evidence by testing threats against production defenses in real time.
Picus Co-founder & CTO Volkan Erturk explained why EV is a game-changer at the 2025 Adversarial Exposure Validation Summit, joined by Gartner analysts, Picus domain experts, and end-user organizations.Watch the session.
Qubitrium Advances in Quantum Communication with New Product and MoD Project
Qubitrium has been selected by the Netherlands Ministry of Defence to lead a Purple NECtar Quantum Challenge project in collaboration with Xairos and QuDef. The team will demonstrate secure, high-precision Quantum Time Transfer (QTT) in GNSS- and RF-denied environments, addressing critical needs in positioning, navigation, and timing.
In parallel, Qubitrium has launched QubitCore, a compact and modular quantum communication module for CubeSats. With full QKD functionality in a 1U (10×10×10 cm) form factor, QubitCore integrates entangled-photon generation, SPAD-based detection, time-stamping, precision temperature control, and zero-trust key management. It weighs less than 1 kilogram and consumes 8 watts of power, making it a commercially available building block for global quantum-secure satellite networks. Qubitrium Co-founder and CEO Kadir Durak introduces QubitCore, a fully integrated QKD module for CubeSats, in this launch video. Watch here.
Cellbricks Demonstrates In Vivo Success and Wins Deep Tech Momentum Bio Track
Cellbricks Therapeutics has announced a major milestone in the validation of its 3D bioprinting platform with the successful completion of an in vivo study using bioprinted adipose tissue. Seven weeks after implantation in mice, the grafts showed full tissue integration, rapid vascularization, and no fibrosis. This marks what is believed to be the world’s first commercial demonstration of seamless host integration for a 3D-bioprinted adipose tissue graft. The study strengthens Cellbricks' lead therapeutic program focused on wound healing and supports its broader clinical vision for functional tissue implants such as liver grafts. The company is planning its first FDA submission by 2027 and recently opened a U.S. office in Boston. A new financing round is underway to support continued preclinical development.
Cellbricks also won the Bio Builders Pitch Competition at Deep Tech Momentum 2025 in Berlin. Selected as the top startup among thirteen competitors in the Bio Builders Track, the team also received three individual investor awards from leading biotech experts and presented on the main stage among all track winners.
Meddenovo Secures Investment from INVEST101
Meddenovo Drug Design has secured a new investment from INVEST101, a fund established by Türkiye Development Fund and ODTÜ TEKNOKENT. Meddenovo applies artificial intelligence, molecular modeling, and peptide-based approaches to accelerate drug discovery by identifying optimal candidates from thousands of possibilities. The new investment will support the completion of product development, team expansion, and commercial growth. It marks a strong vote of confidence in Meddenovo’s technology and progress to date.
